Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 10/20 | 0.50 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.50 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524058 | 0.82 | MAPK1 (0.72) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL6125034 | 0.80 | MAPK1 (0.63) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL358730 | 0.80 | MAPK1 (0.69) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL29394047 | 0.80 | MAPK1 (0.69) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL29580152 | 0.78 | ALDH1A1 (0.64) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL28805237 | 0.78 | MAPK1 (0.67) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL306375 | 0.78 | ALDH1A1 (0.64) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL2257971 | 0.77 | MAPK1 (0.59) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL305611 | 0.77 | MAPK1 (0.62) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 | |
| SCHEMBL5157523 | 0.77 | MAPK1 (0.59) | MAPK1TSHRVCAM1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3961059-A | 6-(Substituted phenoxy)tetrazolo(1,5-b)pyridazines and a method of use for control of soil-borne plant diseases | THE DOW CHEMICAL COMPANY (US) | 1976-06-01 | — | — | US | claimed |
| JP-52131539-A | — | — | None | — | — | JP | disclosed |
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| EP-1081228-B1 | Process for producing carboxylic acid isomer | SUMITOMO CHEMICAL CO (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | SANKYO COMPANY, LIMITED (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1568704-A1 | NOVEL 2' ,5' -OLIGOADENYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-6365399-B1 | EFFICIENT PROCESS FOR PRODUCTION OF CHEMICAL INTERMEDIATES OF DRUGS AND AGRICULTURAL CHEMICALS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-04-02 | — | — | US | disclosed |
| EP-1081228-A2 | Process for producing carboxylic acid isomer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-03-07 | — | — | EP | disclosed |
| JP-S52131539-A | PHENOXYPHENOXYPROPIONIC ACID DERIVATIVES AND HERBICIDES | ISHIHARA SANGYO KAISHA LTD | 1977-11-04 | — | — | JP | disclosed |
| US-3961059-A | 6-(Substituted phenoxy)tetrazolo(1,5-b)pyridazines and a method of use for control of soil-borne plant diseases | THE DOW CHEMICAL COMPANY (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | NSUN2, RNGTT, NSUN3 | MAPK1 2049/4885TSHR 1870/4885VCAM1 4562/4885 |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | ADAR, NSUN2, ADORA3 | MAPK1 4245/4885TSHR 1214/4885VCAM1 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.